Status:
UNKNOWN
Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Lead Sponsor:
State University of New York - Downstate Medical Center
Conditions:
Endothelial Function
Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
We are comparing the blood pressure-lowering effects of two marketed medications, Coreg CR and Toprol XL. Although both drugs reduce blood pressure by blocking the action of noradrenaline on beta-rece...
Detailed Description
The following techniques will be used: Endothelial function will be measured non-invasively by flow-mediated changes in pulsatile blood volume in the finger-tips. Vascular compliance (stiffness) wil...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus,
- Stable antidiabetic regimen for 3 months
- Hemoglobin A1c \<8.6%
- Stable antihypertensive medication regimen for 3 months or more, including either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Exclusion
- Any clinically significant abnormality on history, physical examination, or laboratory testing which could preclude safe completion of the study
- Significant cardiac conditions
- Lung disease
- Cigarette smoking
- Chronic kidney disease (Stage 3 or greater)
- Type 1 diabetes
- Known contraindication to alpha- or beta-blocker therapy
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00732511
Start Date
April 1 2008
End Date
April 1 2009
Last Update
February 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SUNY Downstate Medical Center
Brooklyn, New York, United States, 11203